Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.

Bayesian‐augmented PSA demonstrated a 70% increase in the odds of achieving remission with blinatumomab in comparison with the external SOC, a numerical benefit that did not reach statistical significance.

also in 111,027 other papers